

### SCIENTIFIC PROGRAMME

#### Course Director

Emmanouil Fokas (DE)

#### Faculty

Regina Beets-Tan (NL)

Ane Appelt (UK)

Maria Antonietta Gambacorta (IT)

Rob Glynne-Jones (UK)

Brechtje A. Grotenhuis (NL)

Karin Haustermans (BE)

Corrie A.M. Marijnen (NL)

Claus Rödel (DE)

#### DAY 1 - Wednesday 22 March 2023

			Speaker
	12.00 – 12.45	Registration	
	12.45 – 13.00	Introduction	E. Fokas
<b>Rectal Cancer</b>			
<b>Session 1</b> <b>Standard Diagnosis and Treatment</b> <b>(Pivotal clinical trials and current guidelines)</b>  <b>MODERATION:</b> <b>K. Haustermans</b>	13.00 - 14.20	<b>Lecture (15'+5'):</b> Current (European) Guidelines: What is considered standard of care for radiotherapy (TNM-based, MRI-based RT indications, short-course RT, chemoradiation, TNT)?	C. Marijnen
		<b>Lecture (15'+5'):</b> Current (European) Guidelines: What is considered standard of care for concurrent and induction/adjuvant chemotherapy?	R. Glynne-Jones
		<b>Lecture (15'+5'):</b> Imaging-based initial local and systemic staging (Role of ERUS, MRI): What are standard procedures, recommended in guidelines?	R. Beets-Tan
		<b>Lecture (15'+5'):</b> Surgical concepts/problems after neoadjuvant treatment (sphincter preservation, LE, surgical complications, TME quality).	B. Grotenhuis
	14.20 - 14.30	Coffee break	
<b>MODERATION:</b> <b>C. Rödel/E. Fokas</b>	14.30 - 16.00	<b>Tumorboard: Case presentations (by participants) and questions on standard of care treatment (without organ preservation): Bring your own cases and discuss with experts and other participants</b>	Participants/All teachers
	16.00 - 16.30	Coffee break	
<b>Session 2:</b> <b>RT-Techniques/ dose/constraints/toxicity</b>  <b>MODERATION :</b> <b>C. Marijnen</b>	16.30 - 17.30	<b>Lecture (25'+5'):</b> Dose-response, dose-volume effects and dose constraints	A. Appelt
		<b>Lecture (25'+5):</b> Clinical data on acute and late toxicity, supportive treatment during RT/CRT	M.A. Gambacorta

## DAY 2 - Thursday 23 March 2023

			Speaker
<b>Session 3:</b> <b>RT-delineation</b>  <b>MODERATION :</b> <b>K. Haustermans/  C. Marijnen/MG  Gambacorta</b>	9.00 - 10.30	<b>Teaching (30'): International consensus guideline on CTV delineation (panel)</b>	K. Haustermans
		<b>Exercise (30'): Discussion of FALCON contouring of participants: early stage case</b>	C. Marijnen
		<b>Exercise (30'): Discussion of FALCON contouring of participants: advanced stage case</b>	M.A. Gambacorta
	10.30 - 11.00	Coffee break	
<b>Session 4:</b> <b>Organ Preservation</b>  <b>MODERATION :</b> <b>R. Glynne-Jones</b>	11.00 - 12.15	<b>Lecture (20'+5): Organ preservation: Patient selection/surveillance/salvage: View of surgeon</b>	B. Grotenhuis
		<b>Lecture (20'+5): RT-related aspects: Target volumes/dose/fractionation/combination with chemo/role of brachytherapy</b>	C. Marijnen
		<b>Lecture (20'+5) Role of Imaging: Re-staging/monitoring during/after neoadjuvant/definitive treatment</b>	R. Beets-Tan
	12.15 - 12.30	<b>(10'+5): Organ preservation and TNT: Where do we stand?</b>	C. Rödel
	12.30 - 13.30	Lunch break	
<b>MODERATION:</b> <b>C. Marijnen</b>	13.30 - 14.30	<b>Tumorboard: Case presentations (by participants) and questions on organ preservation: Bring your own cases and discuss with experts and other participants</b>	Participants/All teachers
<b>Session 5:</b> <b>EXERCISE: IMRT/IGRT and MRI monitoring</b>  <b>MODERATION:</b> <b>A. Appelt/R. Beets-Tan</b>	14.30 - 16.00	<b>Exercise: Group 1: IMRT/VMAT/IGRT/adaptive RT: Pitfalls and challenges (45 min, then change)</b>	A. Appelt
		<b>Exercise: Group 2: Functional imaging before, during, after RT: How do read MRI (45 min, then change)</b>	R. Beets-Tan
	16.00 - 16.30	Coffee break	
<b>Session 6:</b> <b>Future perspectives of combined modality treatment for RC</b>  <b>MODERATION :</b> <b>MG Gambacorta</b>	16.30 - 17.30	<b>Lecture (15'+5'): Newer chemotherapy, targeted agents and immunotherapy with or without RT</b>	R. Glynne-Jones
		<b>Lecture (15'+5'): Molecular predictive biomarkers and "omics": Where do we stand, where do we go?</b>	K. Haustermans
		<b>Lecture (15'+5'): Ongoing and planned clinical trials on combined modality treatment for rectal cancer</b>	E. Fokas

## DAY 3 - Friday 24 March 2023

			Speaker
<b>Anal Cancer</b>			
<b>Session 1</b> <b>Standard Treatment</b> <b>(Pivotal clinical trials and current guidelines)</b>  <b>MODERATION:</b> <b>E. Fokas</b>	9.00 - 10.00	<b>Lecture (12'+3')</b> : Imaging-based staging and response evaluation/prediction (Role of MRI, PET-CT) : What is considered standard ?	R. Beets-Tan
		<b>Lecture (12'+3')</b> : Current (European) Guidelines: What is considered standard of care for radiotherapy	E. Fokas
		<b>Lecture (12'+3')</b> : Current (European) Guidelines: What is considered standard of care for concurrent chemotherapy? Role of induction- and adjuvant chemotherapy?	R Glynne-Jones
		<b>Lecture (12'+3')</b> : Role of salvage surgery for non-responders, surgery for locoregional recurrent disease	B. Grotenhuis
	10.00 - 11.00	<b>Tumorboard: Case presentations (by participants): Bring your own cases and discuss with experts and other participants</b>	Participants All teachers
	11.00 - 11.30	Coffee break	
<b>Session 2:</b> <b>Group-Exercise Delineation</b>	11.30 - 13.00	<b>Lecture (30')</b> : Atlas and contouring guidelines for anal cancer radiotherapy	MA Gambacorta
		<b>Exercise (60')</b> : Discussion of FALCON contouring of participants: early/advanced stage cases	C. Marijnen/A. Appelt
	13.00 - 14.00	Lunch break	
<b>MODERATION:</b> <b>MA Gambacorta</b>  <b>Session 3</b> <b>RT-techniques and Supportive care</b>	14.00 - 14.25	<b>Lecture (20'+5')</b> : Treatment planning for anal cancer: state of the art and challenges (IMRT/SIB/adaptive RT)	A. Appelt
<b>MODERATION :</b> <b>A. Appelt/C. Rödel</b>  <b>Session 4</b> <b>Tumor biology</b> <b>Session 5</b> <b>Future perspectives of combined modality treatment for AC</b>	14.25 - 14.50	<b>Lecture (20'+5)</b> : Role of molecular markers (e.g. p16, HPV load, tumor infiltrating lymphocytes). Role of targeted agents?	K. Haustermans
	14.50 - 15.40	<b>Lecture (15'+5')</b> : Ongoing and planned clinical trials	C. Rödel
		<b>Lecture (15'+5')</b> : Clinical endpoints in anal cancer trials	R. Glynne-Jones
		<b>Discussion (20')</b> : Most important research topics and clinical trials. Take home messages	E. Fokas